Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...
Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the Ministry ...
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...
Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...
Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs?cadonilimab Injection (PD-1/CTLA-4 ...
Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. See why SAVA stock is at risk of delisting or merger.
Zacks.com on MSN1d
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage StudyCassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...
Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...
The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...
DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback